Dr Bright said Australia had the opportunity to “scale up”, with bigger trials ensuring more therapists were trained so when MDMA was given the green light in the US, the safety data was available to show it was possible here too.
He said currently none of the Australian studies had been given government funding and there was little incentive for pharmaceutical companies to back this research either.
Dr Bright said he was concerned that if the infrastructure for administering these drugs wasn’t worked into Australia’s health care system, the treatments would be limited to those who could afford them.
